Hot Flashes Pipeline Drugs Report 2025: Comprehensive Insights into Emerging Therapies, Clinical Developments, and Future Market Opportunities | DelveInsight

DelveInsight's "Hot Flashes Pipeline Insight 2025" report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Hot Flashes pipeline landscape. It covers the Hot Flashes pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hot Flashes pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Hot Flashes Pipeline? Click here to explore the therapies and trials making headlines @ Hot Flashes Pipeline Outlook Report [https://www.delveinsight.com/sample-request/hot-flashes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Hot Flashes Pipeline Report

* On 22 September 2025, Astellas Pharma Inc. announced a study will confirm if fezolintant helps reduce the number of hot flashes in Japanese women going through menopause. Women that want to take part in the study will be given an electronic handheld device with an app to track their hot flashes. Some women may be able to use the app on their own smartphone. Before the women are assigned a treatment, they will record information about their hot flashes.
* DelveInsight's Hot Flashes Pipeline report depicts a robust space with 15+ active players working to develop 15+ pipeline therapies for Hot Flashes treatment.
* The leading Hot Flashes Companies, such as Veru Healthcare, Fervent Pharmaceuticals, Ogeda, Bayer, Lundbeck A/S, TherapeuticsMD, MenoGeniX, Mitsubishi Tanabe Pharma, QUE Oncology, Pherin Pharmaceuticals and others.
* Promising Hot Flashes Therapies such as Fezolinetant, NK3R antagonist-AZD4901, Tamoxifen, FP-101, MF101, Gabapentin, RAD1901 and others.

Want to know which companies are leading innovation in Hot Flashes? Dive into the full pipeline insights @ Hot Flashes Clinical Trials Assessment [https://www.delveinsight.com/sample-request/hot-flashes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Hot Flashes Pipeline Report provides a disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The Hot Flashes Pipeline Report also highlights the unmet needs with respect to the Hot Flashes.

Hot Flashes Overview

Hot flashes (HFs) are a rapid and exaggerated heat dissipation response, consisting of profuse sweating, peripheral vasodilation, and feelings of intense, internal heat. They are triggered by small elevations in core body temperature (Tc) acting within a greatly reduced thermoneutral zone, i.e., the Tc region between the upper (sweating) and lower (shivering) thresholds.

Hot Flashes Emerging Drugs Profile

* Fezolinetant: Astellas Pharma

Fezolinetant is an investigational selective neurokinin-3 (NK3) receptor antagonist. The safety and efficacy of fezolinetant are under investigation and have not been established. If approved by regulatory authorities, fezolinetant would be a first-in-class, nonhormonal treatment option to reduce the frequency and severity of VMS associated with menopause.

* Elinzanetant: Bayer

Elinzanetant is a first-in-class, non-hormonal, orally administered, dual neurokinin-1,3 receptor antagonist currently in clinical development for the treatment of vasomotor symptoms during menopause. Elinzanetant addresses vasomotor symptoms by modulating a group of oestrogen sensitive neurons in the hypothalamus in the brain (the KNDy neurons), that due to the absence of oestrogen, become hyperactive in menopausal women and consequently disrupt body heat control mechanisms resulting in the debilitating vasomotor symptoms of hot flashes.

* Fezolinetant: Ogeda

Fezolinetant (ESN364) is a proprietary, oral, small-molecule, discovered and developed by Ogeda for the purpose of the treatment of women's health disorders. Fezolinetant's mechanism of action to mimic the neuronal effects of estrogen to control body temperature supports the use of fezolinetant to directly and safely address the basis for hot flashes in menopausal women. In addition, fezolinetant addresses the cause of PCOS by selectively lowering luteinizing hormone (LH) without affecting follicle-stimulating hormone (FSH) in order to restore the correct LH-to-FSH ratio and permit the restoration of menstrual cycle regularity and fertility. Fezolinetant is also superior to the existing, marketed gonadotropin-releasing hormone (GnRH) ligands as it reduces levels of the ovarian hormones estrogen and progesterone in a non-castrating manner as required for the safe, effective treatment of uterine fibroids and endometriosis.

* Zuclomiphene citrate: Veru Inc

Zuclomiphene citrate is a novel, proprietary, oral, nonsteroidal, estrogen receptor agonist. Today the Company announced that a Phase 2 clinical trial of Zuclomiphene citrate demonstrated a statistically significant reduction in the frequency of moderate to severe hot flashes in men with advanced prostate cancer on ADT therapy.

If you're tracking ongoing Hot Flashes Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Hot Flashes Treatment Drugs [https://www.delveinsight.com/sample-request/hot-flashes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Hot Flashes Pipeline report provides insights into:-

* The report provides detailed insights about companies that are developing therapies for the treatment of Hot Flashes with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hot Flashes Treatment.
* Hot Flashes Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Hot Flashes Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hot Flashes market.

Hot Flashes Companies

Veru Healthcare, Fervent Pharmaceuticals, Ogeda, Bayer, Lundbeck A/S, TherapeuticsMD, MenoGeniX, Mitsubishi Tanabe Pharma, QUE Oncology, Pherin Pharmaceuticals and others.

Hot Flashes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Oral
* Intravenous
* Subcutaneous

Hot Flashes Products have been categorized under various Molecule types such as

* Small molecule
* Thiadiazoles
* Recombinant proteins

From emerging drug candidates to competitive intelligence, the Hot Flashes Pipeline Report covers it all - check it out now @ Hot Flashes Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/hot-flashes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Hot Flashes Pipeline Report

* Coverage- Global
* Hot Flashes Companies- Veru Healthcare, Fervent Pharmaceuticals, Ogeda, Bayer, Lundbeck A/S, TherapeuticsMD, MenoGeniX, Mitsubishi Tanabe Pharma, QUE Oncology, Pherin Pharmaceuticals and others.
* Hot Flashes Therapies- Fezolinetant, NK3R antagonist-AZD4901, Tamoxifen, FP-101, MF101, Gabapentin, RAD1901 and others.
* Hot Flashes Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Hot Flashes Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research - discover what's next for the Hot Flashes Treatment landscape in this detailed analysis @ Hot Flashes Emerging Drugs and Major Players [https://www.delveinsight.com/sample-request/hot-flashes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* Hot Flashes: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Hot Flashes - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Zuclomiphene citrate: Veru Inc
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Avexitide: Eiger BioPharmaceuticals
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* SJX 653: Lundbeck A/S
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Drug name: Company name
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Hot Flashes Key Companies
* Hot Flashes Key Products
* Hot Flashes - Unmet Needs
* Hot Flashes - Market Drivers and Barriers
* Hot Flashes - Future Perspectives and Conclusion
* Hot Flashes Analyst Views
* Hot Flashes Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hot-flashes-pipeline-drugs-report-2025-comprehensive-insights-into-emerging-therapies-clinical-developments-and-future-market-opportunities-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/hot-flashes-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.